Postoperative analgesia and sedation in the adult intensive care unit: A guide to drug selection

Drugs

Volumn 63, Issue 8, 2003, Pages 755-767

  Liu, Linda L ^a,b   Gropper, Michael A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANALGESIC AGENT; DEXMEDETOMIDINE; DIAZEPAM; DIHYDROMORPHINE; FENTANYL; HALOPERIDOL; KETAMINE; LORAZEPAM; METHADONE; MIDAZOLAM; MORPHINE; PROCAINAMIDE; PROPOFOL; SEDATIVE AGENT;

AGITATION; ANXIETY; BRADYCARDIA; BRONCHOSPASM; CLINICAL PROTOCOL; CLINICAL TRIAL; CRITICAL ILLNESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG POTENCY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HISTAMINE RELEASE; HUMAN; HYPERTENSION; HYPOTENSION; ILEUS; INTENSIVE CARE UNIT; INTRACRANIAL HYPERTENSION; INTUBATION; KIDNEY FUNCTION; LIVER FUNCTION; LONG TERM CARE; NAUSEA; OUTCOMES RESEARCH; PAIN ASSESSMENT; POSTOPERATIVE ANALGESIA; PRACTICE GUIDELINE; PRURITUS; RATING SCALE; RESPIRATION DEPRESSION; REVIEW; SCORING SYSTEM; SEDATION; SIDE EFFECT; STRESS; TACHYCARDIA; VOMITING;

ADULT; ANALGESICS; ANXIETY; CLINICAL PROTOCOLS; DECISION MAKING; HUMANS; HYPNOTICS AND SEDATIVES; INTENSIVE CARE; INTENSIVE CARE UNITS; PAIN; PAIN MEASUREMENT; PRACTICE GUIDELINES;

EID: 0037255106     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363080-00003     Document Type: Review

References (76)

1. Lewis KS, Whipple JK, Michael KA, et al. Effect of analgesic treatment on the physiological consequences of acute pain. Am J Hosp Pharm 1994; 51 (12): 1539-54
2. Mangano DT, Siliciano D, Hollenberg M, et al. Postoperative myocardial ischemia: therapeutic trials using intensive analgesia following surgery. Anesthesiology 1992; 76 (3): 342-53
3. Britton BJ, Hawkey C, Wood WG, et al. Stress: a significant factor in venous thrombosis? Br J Surg 1974; 61 (10): 814-20
4. Slade MS, Greenberg LJ, Yunis EJ, et al. Integrated immune response to standard major surgical trauma in normal patients. Surg Forum 1974; 25: 425-7
5. Swinamer DL, Phang PT, Jones RL, et al. Effect of routine administration of analgesia on energy expenditure in critically ill patients. Chest 1988; 93 (1): 4-10
6. Moller IW, Dinesen K, Sondergard S, et al. Effect of patient-controlled analgesia on plasma catecholamine, cortisol and glucose concentrations after cholecystectomy. Br J Anaesth 1988; 61 (2): 160-4
7. Modig J, Borg T, Bagge L, et al. Role of extradural and of general anesthesia in fibrinolysis and coagulation after total hip replacement. Br J Anaesth 1983; 55: 625-9
8. Salomaki TE, Leppaluoto J, Laitinen JO, et al. Epidural versus intravenous fentanyl for reducing hormonal, metabolic and physiologic responses after thoracotomy. Anesthesiology 1993; 79 (4): 672-9
9. Jones C, Griffiths RD, Macmillan RR, et al. Psychological problems occurring after intensive care. Br J Int Care 1994; 2: 46-53
10. Parker M, Schubert W, Shelhamer J, et al. Perceptions of a critically ill patient experiencing therapeutic paralysis in an ICU. Crit Care Med 1984; 12: 69-71
11. Stoll C, Haller M, Briegel J, et al. Health-related quality of life in long-term survivors after treatment with extracorporeal membrane oxygenation (ECMO) for the acute respiratory distress syndrome (ARDS). Anaesthesist 1998; 47 (1): 24-9
12. Bond M. Psychological and psychiatric aspects of pain. Anaesthesia 1978; 33: 355-61
13. Chapman CR, Casey KL, Dubner R, et al. Pain measurement: an overview. Pain 1985; 22 (1): 1-31
14. Ramsay MA, Savege TM, Simpson BR, et al. Controlled sedation with alphaxalone-alphadolone. BMJ 1974; 2 (920): 656-9
15. Shapiro BA. Bispectral index: better information for sedation in the intensive care unit [editorial]? Crit Care Med 1999; 27 (8): 1663-4
16. Glass PS, Bloom M, Kearse L, et al. Bispectral analysis measures sedation and memory effects of propofol, midazolam, isoflurane, and alfentanil in healthy volunteers. Anesthesiology 1997; 86 (4): 836-47
17. Liu J, Singh H, White PF. Electroencephalographic bispectral index correlates with intraoperative recall and depth of propofol-induced sedation. Anesth Analg 1997; 84 (1): 185-9
18. Shah N, Clack S, Chea F, et al. Does bispectral index of EEG correlate with Ramsay sedation score in ICU patients [abstract]? Anesthesiology 1996; 85: A469
19. Frenzel D, Greim C, Sommer C, et al. Is the bispectral index appropriate for monitoring the sedation level of mechanically ventilated surgical ICU patients? Intensive Care Med 2002; 28: 178-83
20. De Deyne C, Struys M, Decruyenaere J, et al. Use of continuous bispectral EEG monitoring to assess depth of sedation in ICU patients. Intensive Care Med 1998; 24 (12): 1294-8
21. Jacobi J, Fraser G, Coursin D, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 2002; 30 (1): 119-41
22. Hsu HO, Hickey RF, Forbes AR. Morphine decreases peripheral vascular resistance and increases capacitance in man. Anesthesiology 1979; 50 (2): 98-102
23. Osborne R, Joel S, Slevin M. Morphine intoxication in renal failure: the role of morphine-6-glucuronide [letter]. BMJ (Clin Res Ed) 1986; 293 (6554): 1101
24. Stanley T, Webster L. Anesthetic requirements and cardiovascular effects of fentanyl-oxygen and fentanyl-diazepam-oxygen anesthesia in man. Anesth Analg 1978; 57: 411-6
25. Bodenham A, Shelly MP, Park GR. The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients. Clin Pharmacokinet 1988; 14 (6): 347-73
26. Haberer J, Schoeffler P, Courderc E, et al. Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. Br J Anaesth 1982; 54: 1267-70
27. Sarhill N, Walsh D, Nelson KA. Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer 2001; 9 (2): 84-96
28. Zheng M, McErlane KM, Ong MC. Hydromorphone metabolites: isolation and identification from pooled urine samples of a cancer patient. Xenobiotica 2002; 32 (5): 427-39
29. Davis MP, Walsh D. Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 2001; 9 (2): 73-83
30. Felder C. Uehlinger C, Baumann P, et al. Oral and intravenous methadone use: some clinical and pharmacokinetic aspects. Drug Alcohol Depend 1999: 55 (1-2): 137-43
31. Irifune M, Shimizu T, Nomoto M, et al. Ketamine-induced anesthesia involves the N-methyl-D-aspartate receptor-channel complex in mice. Brain Res 1992; 596 (1-2): 1-9
32. Gooding J, Dimick A, Tavakoli M, et al. A physiologic analysis of cardiopulmonary responses to ketamine anesthesia in noncardiac patients. Anesth Analg 1977: 56: 813-6
33. Waxman K. Shoemaker W, Lippmann M. Cardiovascular effects of anesthetic induction with ketamine. Anesth Analg 1980; 59: 355-8
34. Joachimsson PO, Hedstrand U. Eklund A. Low-dose ketamine infusion for analgesia during postoperative ventilator treatment. Acta Anaesthesiol Scand 1986; 30 (8): 697-702
35. Corssen G, Gutierrez J, Reves J, et al. Ketamine in the anesthetic management of asthmatic patients. Anesth Analg 1972: 51: 588-96
36. Chang T. Glazko A. Biotransformation and disposition of ketamine. Int Anesthesiol Clin 1974; 12: 157-77
37. Cohen IL. The management of the agitated ICU patient. Crit Care Med 2002; 30 Suppl. 1: S97-123
38. Greenblatt DJ, Shader RI, Franke K, et al. Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. J Pharm Sci 1979; 68 (1): 57-63
39. Pohlman AS, Simpson KP, Hall JB. Continuous intravenous infusions of lorazepam versus midazolam for sedation during mechanical ventilatory support: a prospective, randomized study. Crit Care Med 1994; 22 (8): 1241-7
40. Laine GA, Hossain SMH, Solis RT, et al. Polyethylene glycol nephrotoxicity secondary to prolonged high-dose intravenous lorazepam. Ann Pharmacother 1995; 29 (11): 1110-4
41. Cawley MJ. Short-term lorazepam infusion and concern for propylene glycol toxicity: case report and review. Pharmacotherapy 2001; 21 (9): 1140-4
42. Elliott H. Metabolism of lorazepam. Br J Anaesth 1976; 48: 1017-23
43. Greenblatt D, Shader R, Harmatz J. Benzodiazepines: a summary of pharmacokinetic properties. Br J Clin Pharmacol 1981; 11: 11-6
44. Adams P, Gelman S, Reves JG, et al. Midazolam pharmacodynamics and pharmacokinetics during acute hypovolemia. Anesthesiology 1985; 63 (2): 140-6
45. Malacrida R, Fritz ME, Suter PM, et al. Pharmacokinetics of midazolam administered by continuous intravenous infusion to intensive care patients. Crit Care Med 1992; 20 (8): 1123-6
46. Hall R, Zisook S. Paradoxical reactions to benzodiazepines. Br J Clin Pharmacol 1981; 11: 99S-104S
47. Dirksen MS. Vree TB, Driessen JJ. Clinical pharmacokinetics of long-term infusion of midazolam in critically ill patients: preliminary results. Anaesth Intensive Care 1987; 15 (4): 440-4
48. Reves JG, Fragen RJ, Vinik R, et al. Midazolam pharmacology and uses. Anesthesiology 1985; 62 (3): 310-24
49. Mandema JW, Tuk B, Van Steveninck AL, et al. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 1992; 51 (6): 715-28
50. Hamaoka N, Oda Y, Hase I, et al. Propofol decreases the clearance of midazolam by inhibiting CYP3A4: in vivo and in vitro study [abstract]. Anesthesiology 1999; 91 (3A): A451
51. Ahonen J, Olkkola KT, Salmenpera M. et al. Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting. Anesthesiology 1996; 85 (6): 1246-52
52. Ariano RE, Kassum DA. Aronson KJ. Comparison of sedative recovery time after midazolam versus diazepam administration. Crit Care Med 1994:22 (9): 1492-6
53. Klotz I. Avant G, Hoyumpa A, et al. The effects of age and liver disease on the disposition and elimination of diazepam in adult man [abstract]. J Clin Invest 1975; 55: 347
54. Barr J, Egan TD, Sandoval NF, et al. Propofol dosing regimens for ICU sedation based upon an integrated pharmacokinetic-pharmacodynamic model. Anesthesiology 2001; 95 (2): 324-33
55. Fulton B, Sorkin EM. Propofol: an overview of its pharmacology and a review of its clinical efficacy in intensive care sedation. Drugs 1995; 50 (4): 636-57
56. McLeod G. Dick J, Wallis C, et al. Propofol 2 percent in critically ill patients: effect on lipids. Crit Care Med 1997; 25 (12): 1976-81
57. Possidente C, Rogers F. Osler T, et al. Elevated pancreatic enzymes after extended propofol therapy. Pharmacotherapy 1998; 18: 653-5
58. Badr AE, Mychaskiw II G, Eichhorn JH. Metabolic acidosis associated with a new formulation of propofol. Anesthesiology 2001; 94 (3): 536-8
59. Cremer OL. Moons KG, Bouman EA, et al. Long-term propofol infusion and cardiac failure in adult head-injured patients. Lancet 2001; 357 (9250): 117-8
60. Veroli P, O'Kelly B, Bertrand F, et al. Extrahepatic metabolism of propofol in man during the anhepatic phase of orthotopic liver transplantation. Br J Anaesth 1992; 68 (2): 183-6
61. Morcos WE, Payne JP. The induction of anaesthesia with propofol ('Diprivan') compared in normal and renal failure patients. Postgrad Med J 1985; 61 Suppl. 3: 62-3
62. Fish DN. Treatment of delirium in the critically ill patient. Clin Pharm 1991; 10 (6): 456-66
63. Tesar G, Murray G, Cassem N, et al. Use of haloperidol for acute delirium in intensive care setting. J Clin Psychopharmacol 1985; 5: 344-7
64. Sharma N, Rosman H, Padhi D, et al. Torsades de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 1998; 81: 238-40
65. Coursin D, Coursin D, Maccioli G. Dexmedetomidine. Curr Opin Crit Care 2001; 7 (4): 221-6
66. Belleville JP, Ward DS, Bloor BC, et al. Effects of intravenous dexmedetomidine in humans: I. sedation, ventilation, and metabolic rate. Anesthesiology 1992; 77 (6): 1125-33
67. Scheinin B, Lindgren L, Randell T, et al. Dexmedetomidine attenuates sympathoadrenal responses to tracheal intubation and reduces the need for thiopentone and peroperative fentanyl. Br J Anaesth 1992; 68 (2): 126-31
68. Venn R, Bradshaw C, Spencer R, et al. Preliminary UK experience of dexmedetomidine, a bovel agent for postoeprative sedation in the intensive care unit. Anesthesia 1999; 54: 1136-42
69. Bhana N, Goa KL, McClellan KJ. Dexmedetomidine. Drugs 2000; 59 (2): 263-8
70. Soliman H, Melot C, Vincent J. Sedative and analgesic practice in the intensive care unit: the results of a European survey. Br J Anaesth 2001; 87 (2): 186-92
71. Christensen BV, Thunedborg LP. Use of sedatives, analgesics and neuromuscular blocking agents in Danish ICUs 1996/97: a national survey. Intensive Care Med 1999; 25 (2): 186-91
72. Murdoch S, Cohen A. Intensive care sedation: a review of current British practice. Intensive Care Med 2000; 26 (7): 922-8
73. Shapiro BA, Warren J, Egol AB, et al. Practice parameters for intravenous analgesia and sedation for adult patients in the intensive care unit: an executive summary: Society of Critical Care Medicine. Critical Care Med 1995; 23 (9): 1596-600
74. Ely EW, Baker AM, Dunagan DP, et al. Effect on the duration of mechanical ventilation of identifying patients capable of breathing spontaneously. N Engl J Med 1996; 335 (25): 1864-9
75. Brook AD, Ahrens TS, Schaiff R, et al. Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. Crit Care Med 1999; 27 (12): 2609-15
76. Kress JP, Pohlman AS, O'Connor MF, et al. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000; 342 (20): 1471-7